Ranjan Ray, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1033376017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,068 and has fallen 69.7% since, to $323 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 76 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$614
- Novartis$450
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$368
- Amgen$244
- Impulse Dynamics (USA) Inc.$129
- Abiomed$123
- plus $770 from 16 others
Across 5 payments — averaging $42,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$214K
What the payments were for
- Speaking & faculty fees$241%
- Food & beverage$2,67499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $614 |
| Novartis | 6 | $450 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $368 |
| Amgen | 9 | $244 |
| Impulse Dynamics (USA) Inc. | 1 | $129 |
| Abiomed | 1 | $123 |
| Boehringer Ingelheim | 6 | $113 |
| E.r. Squibb & Sons, L.L.C. | 3 | $90 |
| Irhythm Technologies, Inc. | 3 | $75 |
| Johnson & Johnson | 4 | $55 |
| AstraZeneca | 2 | $47 |
| Pfizer | 2 | $46 |
| Heartflow, Inc. | 3 | $45 |
| Baxter Healthcare | 2 | $44 |
| Paragonix Technologies, Inc. | 1 | $44 |
| Lundbeck LLC | 2 | $43 |
| Cvrx, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| One Lambda, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Cathworks, Inc. | 1 | $26 |
| Boston Scientific | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$258
- ENTRESTO$250
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$156
- LifeVest$121
How this compares
$2,698 in reported general payments places this provider in the 30th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 43 | $1,029,711 |
| EliquisApixaban | 96 | $82,515 |
| EntrestoSacubitril/Valsartan | 62 | $80,041 |
| FarxigaDapagliflozin Propanediol | 41 | $56,649 |
| JardianceEmpagliflozin | 40 | $52,462 |
| Tacrolimus | 39 | $9,387 |
| Repatha SyringeEvolocumab | 12 | $6,539 |
| Bumetanide | 47 | $2,271 |
| Mycophenolate Mofetil | 13 | $1,595 |
| Rosuvastatin Calcium | 59 | $1,460 |
| Losartan Potassium | 128 | $1,430 |
| Atorvastatin Calcium | 121 | $1,085 |
| Metoprolol Succinate | 53 | $937 |
| Potassium Chloride | 35 | $931 |
| Carvedilol | 82 | $898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $46 | $1,112,226139 claims |
| NovartisEntresto | $450 | $80,04162 claims |
| AstraZenecaFarxiga | $47 | $56,64941 claims |
| Boehringer IngelheimJardiance | $113 | $52,46240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Francisco
- Teresa de MarcoSan Francisco$366K
- Liviu KleinSan Francisco$223K
- Marc SimonSan Francisco$114K
- Michael MartynSan Francisco$89K
- Shweta MotiwalaSan Francisco$50K
- Mandar ArasSan Francisco$41K
- Jared HerrSan Francisco$12K
- Michael PhamSan Francisco$9K
- Pooja PrasadSan Francisco$8K
- Richard WrightSanta Monica$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.